Discuss the strategic deployment of European litigation venues for US pharma companies, including the UK High Court litigation, UPC proceedings and EPO
9
All information is kept strictly confidential. Please do not distribute.
Please contact: [email protected] for further information.
oppositions, and compare the impacts on injunction risk, cost exposure, and global settlement dynamics.
Examine how branded and biosimilar companies build, litigate, and defend formulation and delivery patents as core composition claims expire and these assets become the last line of exclusivity.
Discuss how assignor estoppel shapes litigation strategy for biotech companies facing founder-originated patents, and discover the most effective defence, settlement, and risk management strategies.
Explore how evergreening strategies and recent EU regulatory reforms are shaping competition, access, and patent lifecycle management across the pharmaceutical landscape.
How the Canadian and American court system deals with medical treatment and dosage cases, including Janssen Inc. v. Pharmascience Inc. (Supreme Court of Canada).
How enforcement, settlement posture, and leverage change once the first generic or biosimilar has already entered the market.
Discuss disputes where manufacturing processes, scale, or technical constraints ultimately dictated infringement and validity outcomes.
A focused look at litigating patents in India where manufacturing scale, pricing pressure, and public-interest arguments materially affect outcomes.
A practical discussion on how in-house teams decide not to sue despite apparent infringement. Focused on risk, cost, precedent, and internal decision-making rather than legal theory.
How patent disputes reveal weaknesses in claim drafting and specification support, and how litigation outcomes are reshaping prosecution strategy for device portfolios.